Exact Sciences Corporation (EXAS)
Mar 23, 2026 - EXAS was delisted (reason: acquired by ABT)
104.91
+0.99 (0.95%)
Inactive · Last trade price
on Mar 20, 2026
Exact Sciences Revenue
In the year 2025, Exact Sciences had annual revenue of $3.25B with 17.69% growth. Exact Sciences had revenue of $878.38M in the quarter ending December 31, 2025, with 23.12% growth.
Revenue (ttm)
$3.25B
Revenue Growth
+17.69%
P/S Ratio
6.17
Revenue / Employee
$450,971
Employees
7,200
Market Cap
20.03B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 3.25B | 488.12M | 17.69% |
| Dec 31, 2024 | 2.76B | 259.10M | 10.37% |
| Dec 31, 2023 | 2.50B | 415.49M | 19.93% |
| Dec 31, 2022 | 2.08B | 317.19M | 17.95% |
| Dec 31, 2021 | 1.77B | 275.70M | 18.49% |
| Dec 31, 2020 | Pro | Pro | Pro |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionEXAS News
- 6 weeks ago - Exact Sciences to Present New Molecular Residual Disease and Multi-Cancer Early Detection Data at AACR 2026 - Business Wire
- 7 weeks ago - Exact Sciences Named Gallup Exceptional Workplace Award Winner for Third Consecutive Year - Business Wire
- 2 months ago - Marking National Colorectal Cancer Awareness Month, Privia Health Program Achieves 84% Colorectal Cancer Screening Rate Through Industry Collaboration - Business Wire
- 2 months ago - Exact Sciences Stockholders Approve Acquisition by Abbott - Business Wire
- 2 months ago - Exact Sciences Announces Record Fourth Quarter and Full Year 2025 Results - Business Wire
- 2 months ago - Geneoscopy Wins Second Patent Trial and Appeal Board Decision, Invalidating All Challenged Claims of Exact Sciences' '746 Patent - Business Wire
- 3 months ago - Exact Sciences Applauds Passage of Legislation Establishing Medicare Coverage Pathway for Multi-Cancer Early Detection Tests - Business Wire
- 3 months ago - Oncotype DX Breast Recurrence Score® Test Surpasses 2 Million Patients Worldwide - Business Wire